Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health – Page 205

In response to a request from the province of British Columbia (BC), from January 31, 2023 to January 31, 2026, adults (18 and over) in BC will not be subject to criminal charges for the possession of up to 2.5 grams of certain illegal drugs for personal use.

The federal Minister of Mental Health and Addictions and Associate Minister of Health granted the province of British Columbia (BC)’s request for a subsection 56 exemption under the Controlled Drugs and Substances Act for adults (18 years of age and older) in the province to possess small amounts of certain illegal drugs for personal use. BC has referred to this as “decriminalization of personal possession of illegal drugs”.

What this means is that from January 31, 2023 to January 31, 2026, adults (18 and over) in BC will not be subject to criminal charges for the possession of a cumulative total of up to 2.5 grams of certain illegal drugs for personal use. Instead, all individuals found in possession of substances listed in the exemption of up to 2.5 grams for personal use will, at minimum, be provided with information on available local health and social services. They can also be provided with assistance to connect with those services if requested. The exemption only covers possession for personal use by adults (18 and over) in BC with no intent to traffic, produce or export.

British Columbia has been greatly impacted by overdose deaths and related harms, and declared the overdose crisis a public health emergency in 2016. As part of the province’s comprehensive public health response, BC requested a subsection 56 exemption under the Controlled Drugs and Substances Act (CDSA) so that adults in the province will not be subject to criminal charges for personal possession of small amounts of certain illegal drugs.

Read more | >

Tomatoes gene-edited to produce vitamin D, the sunshine vitamin, could be a simple and sustainable innovation to address a global health problem.

Researchers used gene editing to turn off a specific molecule in the plant’s genome which increased provitamin D3 in both the fruit and leaves of tomato plants. It was then converted to vitamin D3 through exposure to UVB light.

Vitamin D is created in our bodies after skin’s exposure to UVB light, but the major source is food. This new biofortified crop could help millions of people with vitamin D insufficiency, a growing issue linked to higher risk of cancer, dementia, and many leading causes of mortality. Studies have also shown that vitamin D insufficiency is linked to increased severity of infection by Covid-19.

Read more | >

Scientists have long known that touching plants can set off a stress reaction in them – but until now it hasn’t been exactly clear how that worked at a molecular level, something that a new study hopes to shed light on.

The researchers behind the study have identified certain genetic keys inside plants that lead to two separate signaling pathways, explaining why plants react so strongly to being touched.

Understanding more about how this process works at a fundamental level could help researchers in a variety of different areas, from improving plant health to getting higher harvest yields from the same crop.

Read more | >

Summary: Researchers have designed a new method of converting non-neural cells into functioning neurons that are able to form synapses, dispense dopamine, and restore the function of neurons undermined by Parkinson’s associated destruction of dopaminergic cells.

Neurodegenerative diseases damage and destroy neurons, ravaging both mental and physical health. Parkinson’s disease, which affects over 10 million people worldwide, is no exception. The most obvious symptoms of Parkinson’s disease arise after the illness damages a specific class of neuron located in the midbrain. The effect is to rob the brain of dopamine—a key neurotransmitter produced by the affected neurons.

In new research, Jeffrey Kordower and his colleagues describe a process for converting non-neuronal cells into functioning neurons able to take up residence in the brain, send out their fibrous branches across neural tissue, form synapses, dispense dopamine and restore capacities undermined by Parkinson’s destruction of dopaminergic cells.

Read more | >

Researchers at Meta’s Artificial Intelligence Research Lab (Facebook) in the U.S. and at the University of Twente’s Neuromechanical Modelling and Engineering Lab in the Netherlands (led by Prof.dr.ir Massimo Sartori), have co-developed the open-source framework MyoSuite, which combines advanced musculoskeletal models with advanced artificial intelligence (AI). The AI-powered digital models in MyoSuite can learn to execute complex movements and interactions with assistive robots, that would otherwise require long experimentations on real human subjects.

Modeling and simulation are now as important to human health technologies as they have been for the advancement of modern automotive industry. Prof. Massimo Sartori: “If we could predict the outcome of a robotic therapy beforehand, then we could optimize it for a patient and deliver a truly personalized and cost-effective treatment.”

MyoSuite supports the co-simulation of AI-powered musculoskeletal systems physically interacting with such as exoskeletons. With MyoSuite you can simulate biological phenomena, e.g., muscle fatigue, muscle sarcopenia, tendon tear and tendon reaffirmation. Moreover, you can simulate how assistive robots could be designed and controlled to restore movement following impairment.

Read more | >

Artificial intelligence (AI) is spreading through society into some of the most important sectors of people’s lives – from health care and legal services to agriculture and transportation.1 As Americans watch this proliferation, they are worried in some ways and excited in others.

In broad strokes, a larger share of Americans say they are “more concerned than excited” by the increased use of AI in daily life than say the opposite. Nearly half of U.S. adults (45%) say they are equally concerned and excited. Asked to explain in their own words what concerns them most about AI, some of those who are more concerned than excited cite their worries about potential loss of jobs, privacy considerations and the prospect that AI’s ascent might surpass human skills – and others say it will lead to a loss of human connection, be misused or be relied on too much.

But others are “more excited than concerned,” and they mention such things as the societal improvements they hope will emerge, the time savings and efficiencies AI can bring to daily life and the ways in which AI systems might be helpful and safer at work. And people have mixed views on whether three specific AI applications are good or bad for society at large.

Read more | >

The bottom of the ocean is full of mysteries but scientists have recently uncovered one of its best-kept secrets. For 25 years, drug hunters have been searching for the source of a natural chemical that had shown promise in initial studies for treating cancer. Now, researchers at University of Utah Health report that easy-to-find soft corals—flexible corals that resemble underwater plants—make the elusive compound.

Identifying the source allowed the researchers to go a step further and find the animal’s DNA code for synthesizing the chemical. By following those instructions, they were able to carry out the first steps of re-creating the soft coral chemical in the laboratory.

“This is the first time we have been able to do this with any drug lead on Earth,” says Eric Schmidt, Ph.D., professor of medicinal chemistry at U of U Health. He led the study with Paul Scesa, Ph.D., postdoctoral scientist and first author, and Zhenjian Lin, Ph.D., assistant research professor.

Read more | >

Cell-Based Dairy Bio-Products For Health & Nutrition — Dr. Aletta Schnitzler, Ph.D. — CSO — Turtletree Labs

Dr. Aletta Schnitzler, PhD. is the Chief Scientific Officer at TurtleTree Labs (https://turtletree.com/) where she leads the R&D teams and spearheads an innovation roadmap to bring nutritious cell-based dairy and meat alternatives to market.

TurtleTree is a biotech company dedicated to producing a new generation of nutrition—one that’s better for the planet, better for the animals, and better for people everywhere. Utilizing its proprietary, cell-based technology, the company is creating “better-for-you” milk ingredients sustainably and affordably, with benefits that extend beyond the dining table and into the heart of humanity.

Previous to joining TurtleTree, Dr. Schnitzler co-founded Merck KGaA’s Cultured Meat Innovation program and directed technology development to advance platforms enabling rapid development, validation and manufacture of cell-based meat products. Focus areas included formulating cost-effective cell culture media, understanding cell line requirements, and envisioning new process templates for biomass generation and structured products.

Additionally, Dr. Schnitzler was Head of Cell Therapy Bioprocess R&D at MilliporeSigma, honing expertise in media optimization and single-use bioreactor systems for use in a complex regulatory environment. She also held technical and marketing roles supporting small-scale chromatography devices and cell culture products for monoclonal antibody production.

Continue reading “Dr Aletta Schnitzler — CSO — TurtleTree Labs — Cell-Based Dairy Bio-Products For Health & Nutrition” | >

UK’s National Grid Electricity Transmission (NGET) is launching trials to fully automate the corrosion inspection of electricity transmission pylons with the help of autonomous drones.

NGET owns 21,900 steel lattice pylons that carry overhead transmission conductor wires in England and Wales. Transmission pylon steelwork conditions can deteriorate through corrosion, so periodic assessments are made to understand the health of the network. NGET inspects around 3,650 steel lattice pylons each year, capturing high definition still color images of steelwork using helicopters and manually-operated drones.

Read more | >

Preparedness For Emerging Diseases & Zoonoses — Dr. Maria Van Kerkhove, Ph.D., Emerging Diseases and Zoonoses Unit Head, World Health Organization, (WHO)

Dr. Maria Van Kerkhove, Ph.D., (https://www.imperial.ac.uk/people/m.vankerkhove) is an infectious disease epidemiologist who serves as the technical lead for the COVID-19 response at the World Health Organization (https://www.who.int/en/), where she develops guidance, training programs, and information products for the continuously evolving state of the pandemic, as well serving as the Emerging Diseases and Zoonoses Unit Head.

Dr. Van Kerkhove began her journey in global health given her interest in viruses and how they infect and impact both humans and animals. She received her undergraduate degree in biological sciences from Cornell University, her master’s degree in epidemiology from Stanford University, and a PhD in infectious disease epidemiology from the London School of Tropical Hygiene and Medicine where she authored her PhD on pathogenic avian influenza H5N1 in Cambodia.

Following her PhD, Dr. Van Kerkhove was a postdoctoral researcher with the WHO and acted as a liaison for the Imperial College London’s Medical Research Council Centre for Outbreak Analysis.

Dr. Van Kerkhove continued working with the WHO and prior to COVID-19, was serving as the MERS-CoV Technical Lead in addition to being the Unit Head for the Emerging Disease and Zoonoses Unit. Her focus in these areas includes developing prevention and control programs around high threat respiratory pathogens.

Continue reading “Dr. Maria Van Kerkhove, PhD — Emerging Diseases and Zoonoses Unit Head — World Health Organization” | >